Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is well-positioned for future success with a strong financial runway through 2029 and a promising pipeline of clinical product candidates targeting molecular causes of aging. Their innovative approach to addressing metabolic diseases by targeting inflammation and the aging process sets them apart from traditional biopharmaceutical companies. The recent announcement of the dosing of the first participant in their QUELL-DME trial is a significant milestone and demonstrates the potential of their NLRP3 inhibitor BGE-102 to improve vision and reduce inflammation. The company's partnership with Lilly and their focus on developing treatments for conditions driven by inflammation further solidifies their potential for success in the industry.

Bears say

Bioage Labs is a clinical-stage biopharmaceutical company developing therapeutic products for metabolic diseases by targeting the biology of human aging. Despite the company's differentiated human datasets and technology platform, the high-stake demanding comparisons and long timelines for potential approvals may lead to financial challenges and delays in bringing their products to market. With a current valuation of around $336 million and a $25 price target, risks for investors include unexpected clinical outcomes, regulatory uncertainty, and a complex and price-sensitive commercial market.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc. (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc. (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.